Delayed iliopsoas abscess following COVID-19 pneumonia

Ryuichiro Takaki; Masaru Ando; Yoshio Satonaga; Michitoshi Yabe; Takamasa Kan; Erika Omote; Shoma Hirota; Sonoe Uchida; Toru Yamasaki; Kosaku Komiya; Kazufumi Hiramatsu

doi:10.1016/j.resinv.2023.10.002

Delayed iliopsoas abscess following COVID-19 pneumonia

Respir Investig. 2024 Jan;62(1):66-68. doi: 10.1016/j.resinv.2023.10.002. Epub 2023 Nov 10.

Authors

Affiliations

¹ Department of Respiratory Medicine, Oita Prefectural Hospital Japan.
² Department of Respiratory Medicine, Oita Prefectural Hospital Japan. Electronic address: mando@oita-u.ac.jp.
³ Department of Respiratory Medicine and Infection Diseases, Oita University Faculty of Medicine Japan.

PMID: 37951084
DOI: 10.1016/j.resinv.2023.10.002

Abstract

Bacterial co-infection has been reported to contribute to a poor prognosis in patients with COVID-19. However, iliopsoas abscess (IPA) has not been previously reported as a comorbidity during the course of COVID-19. We report two cases of IPA in patients with COVID-19 pneumonia. Both patients required prolonged immunosuppressive therapy for COVID-19 pneumonia and developed bacteremia due to Serratia marcescens in one and Staphylococcus aureus in the other. Although immunosuppressive therapy is commonly used for COVID-19 pneumonia with hypoxemia, the comorbidity of IPA may have been underestimated in these cases.

Keywords: Bacteremia; Iliopsoas abscess; SARS-CoV-2; Serratia marcescens; Staphylococcus aureus.

Publication types

Case Reports

MeSH terms

Anti-Bacterial Agents / therapeutic use
COVID-19* / complications
Humans
Psoas Abscess* / drug therapy
Psoas Abscess* / microbiology
Staphylococcal Infections* / complications
Staphylococcal Infections* / drug therapy
Staphylococcus aureus

Substances

Anti-Bacterial Agents